Taiar Ivan, Gomes July Silveira, Jorge Lucas, Ziebold Carolina, Fernandes André, Biokino Renan, Lorencetti Pedro, Brunoni André, Gadelha Ary
Interdisciplinary Laboratory of Clinical Neurosciences (LINC), Department of Psychiatry, Paulista School of Medicine, Federal University of São Paulo (EPM/UNIFESP), São Paulo 04017-030, Brazil.
Department and Institute of Psychiatry, Medical School from São Paulo University, Sao Paulo 01246-903, Brazil.
Brain Sci. 2025 Sep 22;15(9):1021. doi: 10.3390/brainsci15091021.
Intermittent theta burst stimulation (iTBS) has been associated with improvements in the negative symptoms (NSs) of schizophrenia. However, optimizing by shorter protocols remains necessary. Furthermore, understanding their impact on other clinical symptoms, sleep, and autonomic regulation is important to underlying therapeutic effects.
Evaluate the efficacy of an accelerated iTBS protocol on reducing NSs in patients with schizophrenia. We hypothesize a 20% reduction in BNSS scores in the active group, as well as improvements in disorder-related aspects, including sleep patterns, symptoms severity, and cognition.
A double-blind, randomized, sham-controlled clinical trial design will be conducted to test the effects of the accelerated iTBS protocol in 60 participants with schizophrenia (30 active and 30 sham) with moderate NSs. iTBS protocol will consist of four daily sessions, with 600 pulses per session for five consecutive days. Patients will be assessed at three time points (baseline, after intervention and 30 days follow up) for clinical symptoms, cognition and heart rate variability. The primary outcome will be negative symptoms using the Brief Negative Symptom Scale (BNSS). Study register: Brazilian Registry of Clinical Trials (CAEE: 71102823.4.0000.5505).
The accelerated iTBS protocol has demonstrated promising effects on NSs. However, it is still necessary to establish an effective and feasible high-dosage protocol. This study will contribute to optimizing therapeutic protocols for schizophrenia, with a particular focus on clinical applicability. Additionally, it will provide an opportunity to deepen the understanding of the physiological effects of neuromodulation, contributing to the understanding of its underlying mechanisms.
间歇性θ波爆发刺激(iTBS)已被证实与精神分裂症阴性症状(NSs)的改善有关。然而,仍有必要通过更短的方案进行优化。此外,了解其对其他临床症状、睡眠和自主神经调节的影响对于揭示潜在治疗效果至关重要。
评估加速iTBS方案对减少精神分裂症患者阴性症状的疗效。我们假设,与对照组相比,干预组的简明阴性症状量表(BNSS)评分降低20%,且与疾病相关的各个方面,包括睡眠模式、症状严重程度和认知功能均有所改善。
将采用双盲、随机、假刺激对照的临床试验设计,对60例有中度阴性症状的精神分裂症患者(30例接受真刺激,30例接受假刺激)进行加速iTBS方案效果测试。iTBS方案将包括每日4次治疗,每次600个脉冲,连续治疗5天。将在三个时间点(基线、干预后和随访30天)对患者的临床症状、认知功能和心率变异性进行评估。主要结局指标将采用简明阴性症状量表(BNSS)评估阴性症状。研究注册号:巴西临床试验注册中心(CAEE:71102823.4.0000.5505)。
加速iTBS方案已显示出对阴性症状有显著效果。然而,仍需建立一种有效且可行的高剂量方案。本研究将有助于优化精神分裂症的治疗方案,特别关注临床适用性。此外,它将为深入了解神经调节的生理效应提供契机,有助于理解其潜在机制。